Feline immunodeficiency virus, feline leukaemia virus, Toxoplasma gondii, and intestinal parasitic infections in Taiwanese cats

A population consisting of 70 breeder cats, 43 clinical cases, and 16 feral cats was examined for the presence of Toxoplasma gondii, feline immunodeficiency virus (FIV), and feline leukaemia virus (FeLV). No oocysts of T. gondii were observed in 96 faecal samples; faecal samples were not available from the feral cats. Other intestinal parasites identified included Isospora felis (three cats), Isospora rivolta (five), Dipylidium canium (two), Toxocara cati (four), Toxascaris leonina (one), and Ancylostoma sp. (two). Using a kinetics-based enzyme-linked immunosorbent assay on 117 sera including all the feral cats, nine had antibody to T. gondii antigen, three for antigens to FIV, and seven to the p27 antigen of FeLV. Of the nine cats with antibody to T. gondii, only one was also infected with FIV.     

Evaluation of a commercially available hyperimmune plasma product for prevention of naturally acquired pneumonia caused by Rhodococcus equi in foals

OBJECTIVE: To determine efficacy of a commercially available hyperimmune plasma product for prevention of naturally acquired pneumonia caused by Rhodococcus equi in foals. DESIGN: Randomized clinical trial. ANIMALS: 165 foals. PROCEDURE: Foals were randomly assigned to 1 of 2 groups (hyperimmune plasma or nontreated controls). Foals with failure of passive transfer (FPT) of immunity were treated with hyperimmune plasma and evaluated as a third group. Foals that received plasma were given 950 ml between 1 and 10 days of age and between 30 and 50 days of age. A tracheobronchial aspirate was obtained from foals with clinical signs of respiratory tract disease for bacteriologic culture. RESULTS: A significant difference in incidence of pneumonia caused by R equi in foals with adequate passive transfer was not detected between foals that received plasma (19.1%) and nontreated foals (30%). Of 13 foals without FPT that received plasma and developed pneumonia caused by R equi, 12 developed disease prior to administration of the second dose of hyperimmune plasma. Incidence of undifferentiated pneumonia of all causes was not different between groups. CONCLUSION AND CLINICAL RELEVANCE: Intravenous administration of the commercially available hyperimmune plasma was safe, and the product contained high concentrations of anti-R equi antibodies. However, within this limited foal population, the difference in incidence of pneumonia caused by R equi observed between foals that received plasma and control foals was not significant.     

Efficacy of moxidectin 6-month injectable and milbemycin oxime/lufenuron tablets against naturally acquired trichuris vulpis infections in dogs

Efficacy of moxidectin injection (ProHeart 6 Sustained Release Injectable for Dogs, Fort Dodge Animal Health) against naturally acquired infections of Trichuris vulpis was compared with that of milbemycin oxime/lufenuron tablets (Sentinel Flavor Tabs, Novartis Animal Health). Eighteen dogs infected with T. vulpis were ranked by egg counts and randomly allocated to treatment with moxidectin (170 micro g/kg), milbemycin (500 micro g/kg)/lufenuron (10 mg/kg), or to an untreated control group (six dogs per treatment). Dogs were euthanized for worm counting 7 days after treatment. Efficacy of milbemycin/lufenuron against T. vulpis was 99.6 %, compared with 67.5 % for moxidectin. The commercial formulation of milbemycin oxime/lufenuron provided excellent control of whipworm infection, whereas moxidectin demonstrated variable efficacy against this parasite.     

Frequency of isolation and antimicrobial susceptibility patterns of Staphylococcus intermedius and Pseudomonas aeruginosa isolates from canine skin and ear samples over a 6-year period (1992-1997)

Staphylococcus intermedius (S. intermedius) was isolated from 88.6% and 49.4% of skin and ear samples, respectively, during the years 1992 through 1997, and frequency of isolation remained unchanged. More than 95% of all S. intermedius isolates were susceptible to cephalothin and oxacillin, providing support for empirical treatment of canine skin and ear infections with cephalexin. Pseudomonas aeruginosa (P. aeruginosa) was isolated from 7.5% and 27.8% of skin and ear samples, respectively. The frequency of isolation from skin samples increased over the study period. Because of multidrug-resistant profiles for P. aeruginosa isolates, especially for ear isolates, empirical treatment of P. aeruginosa infections is not advisable.     

Postcards from the past: charting the landscape-scale conversion of tropical Australian savanna to closed forest during the 20th century

Repeated sequences of digitised and geo-referenced historical aerial photography provide a powerful means of understanding landscape change. We use this method to demonstrate a landscape wide expansion of closed forest (42% increase in total coverage) in the Australian monsoon tropics over the past five decades. Retrospective habitat suitability models (HSI) of closed forest derived using four landscape measures (drainage distance, slope angle, aspect and elevation) for imagery taken in 1947 correctly forecast the subsequent spatial distribution of the expansion, with topographic fire protection primarily determining the closed-forest distribution. The dynamics of the closed forest-savanna boundary were predicted accurately by generalised linear models, with closed-forest expansion in fire-protected sites along forest edges and regression in the more fire-prone areas. Two factors may plausibly explain the expansion of closed forests. First, eco-ethnographic records stress the skilful use of fire by Aboriginal people in protecting isolated and locally resource-rich closed-forest patches. Second, the recent global increase in atmospheric CO₂ may be changing the competitive balance between savanna and forest by enabling C₃ trees to grow fast enough to escape the fire trap presented by flammable C₄ grasses.     

Effects of milbemycin oxime on adult hookworms in dogs with naturally acquired infections

Previous work indicated that adult Ancylostoma caninum can be removed from experimentally infected dogs, using a formulation of milbemycin oxime at dosage of 0.5 mg/kg of body weight. To determine the efficacy of this treatment in dogs naturally infected with adult hookworms, 24 mixed-breed dogs with patent hookworm infections were purchased from an out-of-state vendor, and 6 male and 6 female dogs were assigned to either a control group or a group that would be treated. Dogs were treated 10 days after their arrival and were euthanatized 1 week after treatment. Beginning 3 days before treatment, fecal samples were collected daily from all dogs, and the number of Ancylostoma eggs per gram of dry weight of feces was determined from each sample. By 1 week after treatment, the mean number of eggs being passed by the treated dogs had dropped from 12,700 to 10 eggs/g of dried feces; there was no apparent change in fecal egg counts for dogs of the control group. At necropsy, the mean number of adult A caninum in dogs of the treated and control groups was 1.3 and 56, respectively; in these naturally infected dogs, efficacy of treatment was calculated to be 97.8%. The mean number of adult Trichuris vulpis recovered in dogs of the control and treated groups at necropsy was 24 and 0, respectively, which yielded treatment efficacy of 100%. Although Uncinaria stenocephala and Toxocara canis appeared also to be removed by use of this dosage, too few dogs were in the study to calculate meaningful efficacies.(ABSTRACT TRUNCATED AT 250 WORDS)     

Equine hyperimmune serum protects mice against Clostridium difficile spore challenge

Clostridium (C.) difficile is a common cause of nosocomial diarrhea in horses. Vancomycin and metronidazole have been used as standard treatments but are only moderately effective, which highlights the need for a novel alternative therapy. In the current study, we prepared antiserum of equine origin against both C. difficile toxins A and B as well as whole-cell bacteria. The toxin-neutralizing activities of the antibodies were evaluated in vitro and the prophylactic effects of in vivo passive immunotherapy were demonstrated using a conventional mouse model. The data demonstrated that immunized horses generated antibodies against both toxins A and B that possessed toxin-neutralizing activity. Additionally, mice treated with the antiserum lost less weight without any sign of illness and regained weight back to a normal range more rapidly compared to the control group when challenged orally with 10⁷ C. difficile spores 1 day after serum injection. These results indicate that intravenous delivery of hyperimmune serum can protect animals from C. difficile challenge in a dose-dependent manner. Hence, immunotherapy may be a promising prophylactic strategy for preventing C. difficile infection in horses.